CATALOGO DEI PRODOTTI DELLA RICERCA

DE NITTO, SIMONE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.851
EU - Europa 1.809
AS - Asia 1.488
SA - Sud America 197
Continente sconosciuto - Info sul continente non disponibili 108
AF - Africa 72
OC - Oceania 7
Totale 6.532
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.736
RU - Federazione Russa 883
SG - Singapore 639
IT - Italia 298
CN - Cina 274
BR - Brasile 161
HK - Hong Kong 159
VN - Vietnam 144
FR - Francia 107
DE - Germania 101
GB - Regno Unito 95
IE - Irlanda 87
SE - Svezia 70
KR - Corea 66
BD - Bangladesh 65
CA - Canada 50
FI - Finlandia 49
ES - Italia 35
IN - India 26
JP - Giappone 24
PL - Polonia 19
TG - Togo 19
ID - Indonesia 16
BJ - Benin 14
MX - Messico 13
CR - Costa Rica 12
NL - Olanda 11
AR - Argentina 9
IL - Israele 9
LT - Lituania 9
NG - Nigeria 9
PH - Filippine 9
BE - Belgio 8
IQ - Iraq 8
SV - El Salvador 8
UA - Ucraina 8
VE - Venezuela 8
AT - Austria 7
CO - Colombia 7
TR - Turchia 7
AU - Australia 6
EC - Ecuador 6
GT - Guatemala 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
GP - Guadalupe 5
IR - Iran 5
MA - Marocco 5
NI - Nicaragua 5
PK - Pakistan 5
SC - Seychelles 5
AE - Emirati Arabi Uniti 4
PY - Paraguay 4
AZ - Azerbaigian 3
CH - Svizzera 3
JO - Giordania 3
KE - Kenya 3
PR - Porto Rico 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
OM - Oman 2
RS - Serbia 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
HT - Haiti 1
IS - Islanda 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MG - Madagascar 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
Totale 6.421
Salva come PNG Salva come JPEG
Città #
Ashburn 436
Singapore 377
San Jose 360
Dallas 336
Moscow 264
Chandler 260
Hong Kong 157
The Dalles 111
Council Bluffs 102
Verona 88
Dublin 84
Beijing 63
Ho Chi Minh City 57
Los Angeles 48
Munich 47
Redmond 37
New York 34
Columbus 33
Milan 33
Buffalo 31
Hanoi 30
Santa Clara 29
Lawrence 26
London 25
Princeton 25
Seattle 25
Helsinki 23
Madrid 23
Tokyo 22
Sindelfingen 20
Wilmington 20
Lomé 19
Redondo Beach 18
Seoul 18
Montreal 16
Orem 16
Turku 16
São Paulo 15
Chicago 14
Cotonou 14
Phoenix 14
Brooklyn 13
Rome 13
Atlanta 12
Jakarta 12
Poplar 12
Frankfurt am Main 11
Houston 11
Southend 11
Warsaw 11
Jacksonville 10
Lappeenranta 10
Abuja 9
McKinney 9
Paris 9
Brussels 8
North Bergen 8
San José 8
San Salvador 8
Amsterdam 7
Ancona 7
Ann Arbor 7
Boston 7
Denver 7
Figino 7
Hải Dương 7
Washington 7
Brasília 6
Charlotte 6
Chennai 6
Guangzhou 6
North Hollywood 6
Tashkent 6
Toronto 6
Turin 6
Vienna 6
Bonndorf 5
Da Nang 5
Guatemala City 5
Haiphong 5
Hangzhou 5
Mexico City 5
San Francisco 5
Baghdad 4
Bari 4
Bexley 4
Biên Hòa 4
Calgary 4
Curitiba 4
Dhaka 4
Fairfield 4
Johannesburg 4
Managua 4
Naples 4
Norwalk 4
Padova 4
Peschiera del Garda 4
Philadelphia 4
Pisa 4
Queens 4
Totale 3.784
Salva come PNG Salva come JPEG
Nome #
Bile Acids Quantification by Liquid Chromatography-Tandem Mass Spectrometry: Method Validation, Reference Range, and Interference Study 222
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 207
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 190
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 185
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 184
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 183
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 181
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 172
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 168
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 167
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 166
Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay 162
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 159
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 158
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 158
Thrombin Generation in Patients with Coronavirus Disease 2019 154
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 154
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 144
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 144
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 141
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 140
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 136
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 136
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 130
Accuracy of screening for hemolysis in plasma samples using a commercial urine dipstick 130
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 126
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 125
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 124
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 123
Monoclonal gammopathy in SARS-CoV-2 infection 122
Evaluation of the acceptability of proposed hemolysis limits for Werfen ACL-TOP 750 CTS 120
Cellular immunity against SARS-CoV-2 depends on the serological status 119
Impact of the COVID-19 pandemic on the volume of laboratory testing 117
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 115
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 111
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 109
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 108
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 108
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 106
Machine learning model comparison in the screening of cholangiocarcinoma using plasma bile acids profiles 103
Impact of water temperature on reconstitution of quality controls for routine hemostasis testing 102
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 94
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 89
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 83
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 77
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 77
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 75
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 75
Niveles séricos de antígeno prostático específico (PSA) tras vacunación primaria con BNT162b2 16
Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2 13
Impacto de la vacunación primaria con BNT162b2 y una dosis de refuerzo homóloga en los anticuerpos IgA contra SARS-CoV-2 en profesionales sanitarios seronegativos 13
Son los anticuerpos IgG e IgM contra los antígenos S y N del SARS-CoV-2 siempre predictores de infección previa por SARS-CoV-2? 11
Totale 6.532
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.401
article - articoli 25.988
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 413
Totale 52.802
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022137 0 0 0 0 12 7 5 7 17 7 27 55
2022/2023659 37 55 58 120 37 138 23 59 67 9 30 26
2023/2024408 20 30 19 46 61 50 44 64 3 22 39 10
2024/20251.091 59 72 41 165 54 55 34 58 135 98 131 189
2025/20263.323 220 189 275 504 811 212 331 181 215 148 125 112
2026/2027738 23 180 118 353 64 0 0 0 0 0 0 0
Totale 6.532